PRAVACHOL is an HMG-CoA reductase inhibitor (statin) indicated:
• To reduce the risk of myocardial infarction, myocardial revascularization
procedures, and cardiovascular mortality in adults with elevated low-density
lipoprotein cholesterol (LDL-C) without clinically evident coronary heart
disease (CHD).
• To reduce the risk of coronary death, myocardial infarction, myocardial
revascularization procedures, stroke or transient ischemic attack, and slow the
progression of coronary atherosclerosis in adults with clinically evident CHD.
• As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.
• As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and
older with heterozygous familial hypercholesterolemia (HeFH).
• As an adjunct to diet for the treatment of adults with:
o Primary dysbetalipoproteinemia.
o Hypertriglyceridemia.
